RU2018142197A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018142197A3 RU2018142197A3 RU2018142197A RU2018142197A RU2018142197A3 RU 2018142197 A3 RU2018142197 A3 RU 2018142197A3 RU 2018142197 A RU2018142197 A RU 2018142197A RU 2018142197 A RU2018142197 A RU 2018142197A RU 2018142197 A3 RU2018142197 A3 RU 2018142197A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1609683.6 | 2016-06-02 | ||
| GBGB1609683.6A GB201609683D0 (en) | 2016-06-02 | 2016-06-02 | Treatment |
| GB1612193.1 | 2016-07-13 | ||
| GBGB1612193.1A GB201612193D0 (en) | 2016-07-13 | 2016-07-13 | Treatment |
| GBGB1612260.8A GB201612260D0 (en) | 2016-07-14 | 2016-07-14 | Treatment |
| GB1612260.8 | 2016-07-14 | ||
| PCT/GB2017/051596 WO2017208018A1 (en) | 2016-06-02 | 2017-06-02 | Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018142197A RU2018142197A (ru) | 2020-07-09 |
| RU2018142197A3 true RU2018142197A3 (ru) | 2020-10-16 |
| RU2766119C2 RU2766119C2 (ru) | 2022-02-08 |
Family
ID=59253827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018142197A RU2766119C2 (ru) | 2016-06-02 | 2017-06-02 | Режим дозирования для гибридного белка gp100-специфичный перенаправляющий tcr-анти-cd3 scfv |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11827688B2 (ru) |
| EP (1) | EP3464380B1 (ru) |
| JP (2) | JP7599819B2 (ru) |
| CN (1) | CN109952319B (ru) |
| AU (1) | AU2017273147B2 (ru) |
| BR (1) | BR112018074748A2 (ru) |
| CA (1) | CA3025894A1 (ru) |
| DK (1) | DK3464380T3 (ru) |
| ES (1) | ES3008636T3 (ru) |
| FI (1) | FI3464380T3 (ru) |
| HR (1) | HRP20250113T1 (ru) |
| HU (1) | HUE070242T2 (ru) |
| LT (1) | LT3464380T (ru) |
| MX (1) | MX2018014863A (ru) |
| PL (1) | PL3464380T3 (ru) |
| PT (1) | PT3464380T (ru) |
| RS (1) | RS66435B1 (ru) |
| RU (1) | RU2766119C2 (ru) |
| SI (1) | SI3464380T1 (ru) |
| SM (1) | SMT202500049T1 (ru) |
| WO (1) | WO2017208018A1 (ru) |
| ZA (1) | ZA201808128B (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113645953B (zh) * | 2019-01-17 | 2025-03-25 | 英美偌科有限公司 | 制剂 |
| GB201901306D0 (en) * | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| GB201909509D0 (en) * | 2019-07-02 | 2019-08-14 | Immunocore Ltd | Peptide-MHC complexes |
| JP2023506765A (ja) | 2019-12-11 | 2023-02-20 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 変化した表面残基を有する設計されたアンキリン反復ドメイン |
| GB202006629D0 (en) | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| GB202010329D0 (en) | 2020-07-06 | 2020-08-19 | Immunocore Ltd | Specific binding molecules |
| WO2023099622A1 (en) * | 2021-12-01 | 2023-06-08 | Immunocore Limited | Treatment |
| CA3250782A1 (en) | 2022-02-20 | 2023-08-24 | Immunocore Ltd | HIV-SPECIFIC BINDING MOLECULES AND TCR |
| WO2024049476A1 (en) * | 2022-08-31 | 2024-03-07 | Immunocore Limited | Compositions and methods for treating cancer that demonstrates decreasing levels of ctdna in a subject |
| WO2025224692A1 (en) | 2024-04-25 | 2025-10-30 | Immunocore Limited | Method of treating cancer using a gene expression signature |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| JP2001519143A (ja) | 1997-10-02 | 2001-10-23 | スノル・モレキュラー・コーポレーション | 可溶性の一本鎖ｔ細胞レセプタータンパク質 |
| US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
| WO1999060120A2 (en) | 1998-05-19 | 1999-11-25 | Avidex Limited | Soluble t cell receptor |
| WO2000023087A1 (en) | 1998-10-21 | 2000-04-27 | Sunol Molecular Corporation | Polyspecific binding molecules and uses thereof |
| AU2001261624A1 (en) | 2000-05-25 | 2001-12-03 | Altor Bioscience Corporation | Modulation of t-cell receptor interactions |
| CN101712721A (zh) | 2000-06-05 | 2010-05-26 | 阿尔托生物科学有限公司 | T细胞受体融合物及共轭物以及其使用方法 |
| US20030017134A1 (en) | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
| PL208712B1 (pl) | 2001-08-31 | 2011-05-31 | Avidex Ltd | Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd |
| EP1485075A4 (en) | 2002-02-20 | 2006-04-26 | Dyax Corp | MHC-PEPTIDE COMPLEX BINDING LIGANDS |
| NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
| EP1558643B1 (en) | 2002-11-09 | 2009-05-27 | Immunocore Ltd. | T cell receptor display |
| GB0227351D0 (en) | 2002-11-22 | 2002-12-31 | Isis Innovation | Soluble T-cell receptors |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| NZ550815A (en) | 2004-05-19 | 2009-04-30 | Immunocore Ltd | Method of improving T cell receptors |
| DK1765860T3 (da) | 2004-05-19 | 2009-03-09 | Immunocore Ltd | Ny-ESO-T.cellereceptor med höj affinitet |
| AU2005247950B2 (en) | 2004-05-27 | 2012-02-02 | Receptor Logic, Inc. | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| US20090042285A1 (en) | 2004-05-27 | 2009-02-12 | Weidanz Jon A | Antibodies at T cell receptor mimics, methods of production and uses thereof |
| US20100062001A1 (en) | 2004-06-09 | 2010-03-11 | Technion Research & Development | Antibodies for selective apoptosis of cells |
| EP1809669A2 (en) | 2004-10-01 | 2007-07-25 | Avidex Ltd | T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents |
| JP2008520227A (ja) | 2004-11-18 | 2008-06-19 | メディジーン リミテッド | 可溶性二官能性タンパク質 |
| GB0511124D0 (en) | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| EP1795599A1 (en) | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
| US20080044413A1 (en) | 2005-12-21 | 2008-02-21 | Hammond Scott A | EphA2 BiTE molecules and uses thereof |
| PT1976880T (pt) | 2005-12-21 | 2016-09-28 | Amgen Res Munich Gmbh | Composições farmacêuticas com resistência a cea solúvel |
| PT2016102E (pt) | 2006-05-03 | 2012-05-15 | Us Gov Health & Human Serv | Recetores de célula t quimérica e materiais relacionados e métodos de uso |
| WO2007143104A2 (en) | 2006-06-01 | 2007-12-13 | Receptor Logic, Ltd. | Antibodies as t cell receptor mimics, methods of production and uses thereof |
| US8216565B2 (en) | 2007-01-12 | 2012-07-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | GP100-specific T cell receptors and related materials and methods of use |
| GB0708585D0 (en) | 2007-05-03 | 2007-06-13 | Queen Mary & Westfield College | Novel antibody and use in diagnosis and therapy of arthropathies |
| TWI365185B (en) | 2008-07-24 | 2012-06-01 | Lilly Co Eli | Amidophenoxyindazoles useful as inhibitors of c-met |
| GB0816096D0 (en) | 2008-09-04 | 2008-10-15 | Medigene Ltd | Diabetes t cell receptors |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| EP2475996A1 (en) | 2009-09-11 | 2012-07-18 | F. Hoffmann-La Roche AG | Method to identify a patient with an increased likelihood of responding to an anti-cancer agent |
| JP6276175B2 (ja) * | 2011-04-28 | 2018-02-07 | アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング | 潜在的有害作用リスクのある患者にＣＤ１９ｘＣＤ３二特異性抗体を投与するための投薬レジメン |
| PE20141454A1 (es) | 2011-05-06 | 2014-10-23 | Us Gov Health & Human Serv | Inmunotoxina recombinante dirigida a la mesotelina |
| US20150104392A1 (en) | 2013-10-04 | 2015-04-16 | Aptose Biosciences Inc. | Compositions, biomarkers and their use in the treatment of cancer |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| JP6655061B2 (ja) * | 2014-07-29 | 2020-02-26 | ノバルティス アーゲー | 状態を治療するためのｉｌ−１５およびｉｌ−１５ｒアルファヘテロ二量体用量増加レジメン |
| PT3699198T (pt) * | 2014-11-17 | 2025-04-29 | Regeneron Pharma | Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20 |
| EP3794035A1 (en) | 2018-05-14 | 2021-03-24 | Immunocore Limited | Bifunctional binding polypeptides |
-
2017
- 2017-06-02 WO PCT/GB2017/051596 patent/WO2017208018A1/en not_active Ceased
- 2017-06-02 US US16/305,838 patent/US11827688B2/en active Active
- 2017-06-02 LT LTEPPCT/GB2017/051596T patent/LT3464380T/lt unknown
- 2017-06-02 AU AU2017273147A patent/AU2017273147B2/en active Active
- 2017-06-02 SI SI201731581T patent/SI3464380T1/sl unknown
- 2017-06-02 MX MX2018014863A patent/MX2018014863A/es unknown
- 2017-06-02 RS RS20250088A patent/RS66435B1/sr unknown
- 2017-06-02 PL PL17734131.0T patent/PL3464380T3/pl unknown
- 2017-06-02 SM SM20250049T patent/SMT202500049T1/it unknown
- 2017-06-02 DK DK17734131.0T patent/DK3464380T3/da active
- 2017-06-02 HR HRP20250113TT patent/HRP20250113T1/hr unknown
- 2017-06-02 EP EP17734131.0A patent/EP3464380B1/en active Active
- 2017-06-02 CA CA3025894A patent/CA3025894A1/en active Pending
- 2017-06-02 HU HUE17734131A patent/HUE070242T2/hu unknown
- 2017-06-02 BR BR112018074748-3A patent/BR112018074748A2/pt unknown
- 2017-06-02 PT PT177341310T patent/PT3464380T/pt unknown
- 2017-06-02 ES ES17734131T patent/ES3008636T3/es active Active
- 2017-06-02 FI FIEP17734131.0T patent/FI3464380T3/fi active
- 2017-06-02 CN CN201780048564.4A patent/CN109952319B/zh active Active
- 2017-06-02 RU RU2018142197A patent/RU2766119C2/ru active
- 2017-06-02 JP JP2018562926A patent/JP7599819B2/ja active Active
-
2018
- 2018-11-30 ZA ZA2018/08128A patent/ZA201808128B/en unknown
-
2022
- 2022-08-04 JP JP2022125007A patent/JP7417678B2/ja active Active
-
2023
- 2023-10-19 US US18/489,854 patent/US20240052011A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109952319A (zh) | 2019-06-28 |
| JP7599819B2 (ja) | 2024-12-16 |
| EP3464380B1 (en) | 2024-11-06 |
| PT3464380T (pt) | 2025-02-06 |
| US20240052011A1 (en) | 2024-02-15 |
| CA3025894A1 (en) | 2017-12-07 |
| US20200040055A1 (en) | 2020-02-06 |
| RU2018142197A (ru) | 2020-07-09 |
| DK3464380T3 (da) | 2025-02-03 |
| CN109952319B (zh) | 2023-08-25 |
| HRP20250113T1 (hr) | 2025-03-28 |
| ZA201808128B (en) | 2020-05-27 |
| FI3464380T3 (fi) | 2025-01-31 |
| WO2017208018A1 (en) | 2017-12-07 |
| RS66435B1 (sr) | 2025-02-28 |
| MX2018014863A (es) | 2019-09-11 |
| EP3464380A1 (en) | 2019-04-10 |
| HUE070242T2 (hu) | 2025-05-28 |
| AU2017273147A1 (en) | 2019-01-03 |
| JP7417678B2 (ja) | 2024-01-18 |
| SI3464380T1 (sl) | 2025-03-31 |
| JP2019517499A (ja) | 2019-06-24 |
| BR112018074748A2 (pt) | 2019-03-06 |
| SMT202500049T1 (it) | 2025-03-12 |
| ES3008636T3 (en) | 2025-03-24 |
| RU2766119C2 (ru) | 2022-02-08 |
| US11827688B2 (en) | 2023-11-28 |
| PL3464380T3 (pl) | 2025-03-31 |
| JP2022160579A (ja) | 2022-10-19 |
| AU2017273147B2 (en) | 2024-06-13 |
| LT3464380T (lt) | 2025-02-10 |